Period:
Draw Mode:
| Volume | 75,185 |
|
|||||
| News | - | ||||||
| Day High | 0.322 | Low High |
|||||
| Day Low | 0.30 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BiomX Inc | PHGE | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.001 | 0.33% | 0.3011 | 13:20:37 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.3001 | 0.30 | 0.322 | 0.3001 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 174 | 75,185 | $ 0.3059302 | $ 23,001 | - | 0.132 - 1.17 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:25:57 | 5 | $ 0.318 | USD |
BiomX Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 13.84M | 45.98M | 30.76M | $ - | $ - | 0.20 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 1.12M | 10.80% |
BiomX News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHGE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.29 | 0.376 | 0.27816 | 0.3419777 | 636,069 | 0.0111 | 3.83% |
| 1 Month | 0.2774 | 0.376 | 0.2397 | 0.3122322 | 250,820 | 0.0237 | 8.54% |
| 3 Months | 0.50 | 0.5199 | 0.22 | 0.3188088 | 217,410 | -0.1989 | -39.78% |
| 6 Months | 0.30 | 0.69 | 0.132 | 0.2902628 | 375,854 | 0.0011 | 0.37% |
| 1 Year | 0.70 | 1.17 | 0.132 | 0.480553 | 274,618 | -0.3989 | -56.99% |
| 3 Years | 5.62 | 9.0495 | 0.132 | 1.39 | 120,146 | -5.32 | -94.64% |
| 5 Years | 10.65 | 11.05 | 0.132 | 1.59 | 103,828 | -10.35 | -97.17% |
BiomX Description
| BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. |